The Johns Hopkins Cancer Center is dedicated to research and education in cancer and related disorders and to the prompt application of new knowledge to the treatment of patients and to the prevention of neoplastic diseases. This application requests continued CCSG support for the Johns Hopkins Cancer Center's research programs and shared resources. The Johns Hopkins Cancer Center is a multidisciplinary, interdepartmental institute of the Johns Hopkins University. There is a broad base of ongoing cancer research at Johns Hopkins. The special scientific programs of the Cancer Center are interdisciplinary in character and are focused on human disease. A wide range of activity is encompassed ranging from fundamental research into the molecular genetics of human tumorigenesis to clinical trials of new antitumor treatments. The six major research programs of the Center are: Cancer Biology (Baylin), Hematologic Malignancies (Grever), Urologic Oncology (Coffey), Gastrointestinal Cancer (Hamilton), Cancer Prevention and Control (Groopman), Solid Tumor Research (Donehower). There is one developing program in Breast Cancer Research (Davidson). Sixteen Shared Resources currently support the needs of Center investigators. Electron Microscopy, Flow Cytometry, Experimental Irradiators, Animal Resources, Facilities and Common Equipment, Glassware Washing, Human Tissue and Pathology, Cytogenetics and Molecular Genetics, Graft Engineering, Pharmacologic Analytic, Biostatistics, Clinics Research Office, Research Pharmacy and Research Nursing are existing CCSG funded CORES. We are also asking for support for two new resources, the Genetics Research CORE and Research Computing. Interdisciplinary research seminars and research training programs provide valuable opportunities for interdisciplinary interaction and collaboration. Cancer Center developmental funds are used to support faculty recruitment and innovative research. Special emphasis is placed on pilot projects that have the potential for peer-reviewed funded translational research, innovative clinical trials, methodology research and interdisciplinary initiatives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-35
Application #
2414027
Study Section
Cancer Centers and Research Programs Review Committee (CCRP)
Project Start
1978-01-01
Project End
2001-04-30
Budget Start
1997-05-07
Budget End
1998-04-30
Support Year
35
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:

Showing the most recent 10 out of 2393 publications